Company intelligence / Profile preview

Grapheal

Grenoble, Auvergne-Rhône-Alpes, Francegrapheal.com ↗

Ownership: Private
Employees: ~4
Development stage: Preclinical

Overview

Grapheal has developed proprietary graphene-based biosensors integrated into digital test strips and wearables. Its WoundLAB smart patch enables remote monitoring of wound healing via smartphone connectivity. The TestNPass rapid diagnostic test targets infectious disease screening such as COVID. Both are undergoing clinical or field validation with promising early results.

Therapeutic areas: DermatologyInfectious Diseases
Modalities: Device (biosensor)Wearable deviceDigital health platformNanomaterial-based sensor (graphene-based)
Industry: Physiological Monitoring

Partnerships

CEA (French Alternative Energies and Atomic Energy Commission)Ifremer (French Research Institute for Exploitation of the Sea)CNRS Neel InstituteGrenoble University UGASATT LinksiumGraphene Flagship EU program

Beyond the preview

Go deeper on Grapheal.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grapheal.

Explore the full profile